PROM1 and lung cancer: For example, CD133 and CD44 aptamer-conjugated dual-targeted nanomicelles loaded with gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, more effectively eradicated CD133/CD44 double-positive lung cancer-initiating cells compared with the single-targeted or non-targeted nanomicelles [142].